These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21890735)

  • 1. Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition.
    Meisenheimer PL; Uyeda HT; Ma D; Sobol M; McDougall MG; Corona C; Simpson D; Klaubert DH; Cali JJ
    Drug Metab Dispos; 2011 Dec; 39(12):2403-10. PubMed ID: 21890735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
    Li AP
    Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
    Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
    Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction.
    Doshi U; Li AP
    J Biomol Screen; 2011 Sep; 16(8):903-9. PubMed ID: 21832258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes.
    Draper AJ; Madan A; Smith K; Parkinson A
    Drug Metab Dispos; 1998 Apr; 26(4):299-304. PubMed ID: 9531515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Biotransformation of Two Human CYP3A Probe Substrates and Their Inhibition during Early Zebrafish Development.
    Verbueken E; Alsop D; Saad MA; Pype C; Van Peer EM; Casteleyn CR; Van Ginneken CJ; Wilson J; Van Cruchten SJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of cytochrome P450 activity in mice.
    Roncoroni C; Rizzi N; Brunialti E; Cali JJ; Klaubert DH; Maggi A; Ciana P
    Pharmacol Res; 2012 May; 65(5):531-6. PubMed ID: 22391453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of three parallel cytochrome P450 enzyme affinity detection systems coupled on-line to gradient high-performance liquid chromatography.
    Kool J; van Liempd SM; van Rossum H; van Elswijk DA; Irth H; Commandeur JN; Vermeulen NP
    Drug Metab Dispos; 2007 Apr; 35(4):640-8. PubMed ID: 17251308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
    Lee E; Shon JC; Liu KH
    Biopharm Drug Dispos; 2016 Sep; 37(6):366-72. PubMed ID: 27323294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.
    Tang J; Amin Usmani K; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Apr; 147(3):319-29. PubMed ID: 15135087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
    Li P; Lu C; Balani SK; Gan LS
    Drug Metab Dispos; 2011 Jun; 39(6):1054-7. PubMed ID: 21393461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related Differences in CYP3A Abundance and Activity in the Liver of the Göttingen Minipig.
    Van Peer E; De Bock L; Boussery K; Van Bocxlaer J; Casteleyn C; Van Ginneken C; Van Cruchten S
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):350-7. PubMed ID: 25892190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation.
    Madan A; Parkinson A; Faiman MD
    Alcohol Clin Exp Res; 1998 Sep; 22(6):1212-9. PubMed ID: 9756035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
    Lu H; Waxman DJ
    Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New bioluminogenic substrates for monoamine oxidase assays.
    Zhou W; Valley MP; Shultz J; Hawkins EM; Bernad L; Good T; Good D; Riss TL; Klaubert DH; Wood KV
    J Am Chem Soc; 2006 Mar; 128(10):3122-3. PubMed ID: 16522074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thin-layer chromatography analysis of human CYP3A-catalyzed testosterone 6beta-hydroxylation.
    Waxman DJ; Chang TK
    Methods Mol Biol; 2006; 320():133-41. PubMed ID: 16719384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
    Pearce RE; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.